Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

Hammoud, Rola, Drucker, Daniel J. · 2023 · Nature Reviews Endocrinology

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion. The emergence of GIP receptor (GIPR)-GLP1 receptor (GLP1R) co-agonists has fostered growing interest in the actions of GIP and GLP1 in metabolically relevant tissues. Here, we update concepts of how these hormones act beyond the pancreas. The actions of GIP and GLP1 on liver, muscle and adipose tissue, in the control of glucose and lipid homeostasis, are discussed in the context of plausible mechanisms of action. Both the GIPR and GLP1R are expressed in the central nervous system, wherein receptor activation produces anorectic effects enabling weight loss. In preclinical studies, GIP and GLP1 reduce atherosclerosis. Furthermore, GIPR and GLP1R are expressed within the heart and immune system, and GLP1R within the kidney, revealing putative mechanisms linking GIP and GLP1R agonism to cardiorenal protection. We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPR-GLP1R co-agonist tirzepatide, as well as the GIPR antagonist-GLP1R agonist AMG-133. Collectively, we update translational concepts of GIP and GLP1 action, while highlighting gaps, areas of uncertainty and controversies meriting ongoing investigati…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41574-022-00783-3

Cites

191 of 191 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 191 references

Research works printed but not linked: 1

  1. Ast, J., Broichhagen, J. & Hodson, D. J. Reagents and models for detecting endogenous GLP1R and GIPR. eBioMedicine 74, 103739 (2021).

Cited by

See all 246

Metadata

Authors
Hammoud, R., & Drucker, D. J.
Affiliations
Mount Sinai Hospital (CA)
Corresponding author
Drucker, Daniel J.
Venue
Nature Reviews Endocrinology
Published
2022-12-12
Volume
19
Issue
4
Pages
201-216
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W4311182072
Cited by
244
References
191
Citations by year
2026: 58 · 2025: 76 · 2024: 60 · 2023: 50
FWCI
6.69
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research (15432_1)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretins, GIP receptor, GLP-1 receptor, glucose homeostasis, lipid homeostasis, liver, skeletal muscle, adipose tissue, central nervous system, anorectic effect, weight loss, obesity, type 2 diabetes, tirzepatide, atherosclerosis, cardiorenal protection, immune system, kidney, heart
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucose, Humans, Pancreas, Receptors, Gastrointestinal Hormone, Weight Loss, Receptors, G-Protein-Coupled, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. https://app.cochat.ai/papers/10.1038/s41574-022-00783-3
The paper
Hammoud, R., & Drucker, D. J. (2023). Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-022-00783-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.